Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
April 1, 2016
RegMed’s close: No joke, the sector bounced up and stayed
March 28, 2016
RegMed’s close: another roller coaster ride as the nausea returns for some
March 24, 2016
RegMed’s close: stock pricing battled for appreciation as the session closed for a holiday weekend
March 23, 2016
RegMed’s close: the sector downdrafts, I can’t resist - a told you so!
March 22, 2016
RegMed’s close: the process of investing – speculation
March 19, 2016
RegMed’s close: options expiration seemed to be a non-event as volatility swung lower
March 17, 2016
RegMed’s close: another dip on low volume and a reset to a positive close
March 16, 2016
RegMed’s close: the sector has reacted poorly to good news and strongly to a bad news.
March 14, 2016
RegMed’s close: the sector climbs out of its hole
March 10, 2016
RegMed’s close: any news or positives were sold into
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.